http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2208605-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J53-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1995-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66a6fc4b24bc915e3b31b4d62629bf68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69f32d2fa709c3c7939390217fb4204a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fde51a25dfb1f36af02a421550bce10e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f8841504e6e5be7a9c112290f963af1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bed977adf1c5875d09661e4272b6897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4fcc653857f5dbc70058d0022b4fb59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49a7c62ea49d3994425097aa082531d5 |
| publicationDate | 1996-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2208605-A1 |
| titleOfInvention | 14.alpha.,17.alpha.-c2-bridged 19-nor-progesterone derivatives |
| abstract | The invention concerns 14,17-C2-bridged steroids of general formula (I), wherein: R3 represents an oxygen atom, the hydroxy amino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group at the a or,.beta. position, R6' and R7 then representing hydrogen atoms; or alternatively, R6 represents a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group, R6' and R7 then representing a common additional bond; R7 represents a C1-C4 alkyl group at the a or .beta. position, R6 and R6' then representing hydrogen atoms; or alternatively R6 and R7 together represent a methylene group at the a or .beta. position and R6' represents a hydrogen atom; or R6 and R6' together represent an ethylene or methylene group and R7 represents a hydrogen atom; R9 and R10 each represent a hydrogen atom or a common bond; R11 and R12 each represent a hydrogen atom or a common bond; R13 represents a methyl or ethyl group; R15 represents a hydrogen atom or a C1-C3 alkyl group; R16 and R16' independently of one another represent a hydrogen atom, a C1-C3 alkyl group, or a C2-C4 alkenyl group, or together represent a C1-C3 alkylidene group; R15 and R16 represent a common bond and R16' represents a hydrogen atom or a C1-C3 alkyl group, or alternatively R15 and R16 together represent a ring of the partial formula (i) shown, in which n = 1 and 2 and X represents a methylene group or an oxygen atom; and R16' represents a hydrogen atom; R17 1 represents a hydrogen atom or a C1-C3 alkyl group; R17 2 represents a hydrogen atom, a C1-C3 alkyl group or a C2-C4 alkenyl group; R17 1' and R17 2' each represent a hydrogen atom or a common bond; R21 represents a hydrogen atom or a C1-C3 alkyl group; and R21' represents a hydrogen atom, C1-C3 alkyl group or hydroxy group. The claimed compounds do not include 14,17-ethano-19-norpregn-4-en-3,20-dione. The novel compounds, unlike the one disclaimed, show a high level of gestagenic activity even after peroral administration and are suitable for use in the production of medicaments. |
| priorityDate | 1994-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.